High-dose cisplatin and mitomycin C in advanced non-small cell lung cancer

a phase II study of the Northern California Oncology Group

David R Gandara, Edith A. Perez, Howard Wold, Vincent Caggiano, Mary Malec, David K. Ahn, Frederick J Meyers, Robert W. Carlson

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

To investigate chemotherapeutic dose intensity in advanced non-small-cell lung cancer (NSCLC), we evaluated a pharmacokinetically designed schedule of high-dose cisplatin (200 mg/m2 per 28-day cycle) plus mitomycin C. Between March 1987 and March 1989, 62 patients were registered for a phase II study of the Northern California Oncology Group (NCOG). The treatment schedule consisted of cisplatin in hypertonic saline given on a divided days 1 and 8 schedule (100 mg/m2 on each day) plus mitomycin C given at a dose of 8 mg/m2 on day 1 of each cycle. In 61 patients evaluable for response analysis, the overall response rate was 39% (24/61), with a complete response being achieved in 6% (4/61) of cases and a partial response, in 33% (20/61). The response according to reviewed histologic subtype included squamous, 53% of patients (10/19); large cell, 31% (4/13); and adenocarcinoma, 34% (10/29). The median survival for all patients was 19.3 weeks. The mean cisplatin and mitomycin C delivered dose intensities in this study were 45 mg/m2 per week (90% of the projected dose) and 1.5 mg/m2 per week (75%). The toxicity of this combination regimen in the 62 enrolled patients was significant but manageable. Leukopenia (WBC, <1,000/mm3) and thrombocytopenia (platelets, <25,000/mm3) occurred in 3# and 8% of patients treated, respectively. Dose-limiting renal toxicity and clinically significant ototoxicity developed in 8 patients each (13%), and a peripheral sensory neuropathy was observed in 17 cases (27%). Whether this type of dose-intensive therapy results in an improved therapeutic index in NSCLC is currently being evaluated in a randomized comparative trial versus standard-dose cisplatin therapy.

Original languageEnglish (US)
Pages (from-to)243-247
Number of pages5
JournalCancer Chemotherapy and Pharmacology
Volume27
Issue number3
DOIs
StatePublished - May 1990

Fingerprint

Oncology
Mitomycin
Non-Small Cell Lung Carcinoma
Cisplatin
Cells
Toxicity
Appointments and Schedules
Platelets
Leukopenia
Peripheral Nervous System Diseases
Therapeutics
Thrombocytopenia
Adenocarcinoma
Blood Platelets
Kidney
Survival

ASJC Scopus subject areas

  • Pharmacology
  • Oncology
  • Cancer Research

Cite this

High-dose cisplatin and mitomycin C in advanced non-small cell lung cancer : a phase II study of the Northern California Oncology Group. / Gandara, David R; Perez, Edith A.; Wold, Howard; Caggiano, Vincent; Malec, Mary; Ahn, David K.; Meyers, Frederick J; Carlson, Robert W.

In: Cancer Chemotherapy and Pharmacology, Vol. 27, No. 3, 05.1990, p. 243-247.

Research output: Contribution to journalArticle

Gandara, David R ; Perez, Edith A. ; Wold, Howard ; Caggiano, Vincent ; Malec, Mary ; Ahn, David K. ; Meyers, Frederick J ; Carlson, Robert W. / High-dose cisplatin and mitomycin C in advanced non-small cell lung cancer : a phase II study of the Northern California Oncology Group. In: Cancer Chemotherapy and Pharmacology. 1990 ; Vol. 27, No. 3. pp. 243-247.
@article{b300a06e9d5f428995fc99fa6b523623,
title = "High-dose cisplatin and mitomycin C in advanced non-small cell lung cancer: a phase II study of the Northern California Oncology Group",
abstract = "To investigate chemotherapeutic dose intensity in advanced non-small-cell lung cancer (NSCLC), we evaluated a pharmacokinetically designed schedule of high-dose cisplatin (200 mg/m2 per 28-day cycle) plus mitomycin C. Between March 1987 and March 1989, 62 patients were registered for a phase II study of the Northern California Oncology Group (NCOG). The treatment schedule consisted of cisplatin in hypertonic saline given on a divided days 1 and 8 schedule (100 mg/m2 on each day) plus mitomycin C given at a dose of 8 mg/m2 on day 1 of each cycle. In 61 patients evaluable for response analysis, the overall response rate was 39{\%} (24/61), with a complete response being achieved in 6{\%} (4/61) of cases and a partial response, in 33{\%} (20/61). The response according to reviewed histologic subtype included squamous, 53{\%} of patients (10/19); large cell, 31{\%} (4/13); and adenocarcinoma, 34{\%} (10/29). The median survival for all patients was 19.3 weeks. The mean cisplatin and mitomycin C delivered dose intensities in this study were 45 mg/m2 per week (90{\%} of the projected dose) and 1.5 mg/m2 per week (75{\%}). The toxicity of this combination regimen in the 62 enrolled patients was significant but manageable. Leukopenia (WBC, <1,000/mm3) and thrombocytopenia (platelets, <25,000/mm3) occurred in 3# and 8{\%} of patients treated, respectively. Dose-limiting renal toxicity and clinically significant ototoxicity developed in 8 patients each (13{\%}), and a peripheral sensory neuropathy was observed in 17 cases (27{\%}). Whether this type of dose-intensive therapy results in an improved therapeutic index in NSCLC is currently being evaluated in a randomized comparative trial versus standard-dose cisplatin therapy.",
author = "Gandara, {David R} and Perez, {Edith A.} and Howard Wold and Vincent Caggiano and Mary Malec and Ahn, {David K.} and Meyers, {Frederick J} and Carlson, {Robert W.}",
year = "1990",
month = "5",
doi = "10.1007/BF00685721",
language = "English (US)",
volume = "27",
pages = "243--247",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - High-dose cisplatin and mitomycin C in advanced non-small cell lung cancer

T2 - a phase II study of the Northern California Oncology Group

AU - Gandara, David R

AU - Perez, Edith A.

AU - Wold, Howard

AU - Caggiano, Vincent

AU - Malec, Mary

AU - Ahn, David K.

AU - Meyers, Frederick J

AU - Carlson, Robert W.

PY - 1990/5

Y1 - 1990/5

N2 - To investigate chemotherapeutic dose intensity in advanced non-small-cell lung cancer (NSCLC), we evaluated a pharmacokinetically designed schedule of high-dose cisplatin (200 mg/m2 per 28-day cycle) plus mitomycin C. Between March 1987 and March 1989, 62 patients were registered for a phase II study of the Northern California Oncology Group (NCOG). The treatment schedule consisted of cisplatin in hypertonic saline given on a divided days 1 and 8 schedule (100 mg/m2 on each day) plus mitomycin C given at a dose of 8 mg/m2 on day 1 of each cycle. In 61 patients evaluable for response analysis, the overall response rate was 39% (24/61), with a complete response being achieved in 6% (4/61) of cases and a partial response, in 33% (20/61). The response according to reviewed histologic subtype included squamous, 53% of patients (10/19); large cell, 31% (4/13); and adenocarcinoma, 34% (10/29). The median survival for all patients was 19.3 weeks. The mean cisplatin and mitomycin C delivered dose intensities in this study were 45 mg/m2 per week (90% of the projected dose) and 1.5 mg/m2 per week (75%). The toxicity of this combination regimen in the 62 enrolled patients was significant but manageable. Leukopenia (WBC, <1,000/mm3) and thrombocytopenia (platelets, <25,000/mm3) occurred in 3# and 8% of patients treated, respectively. Dose-limiting renal toxicity and clinically significant ototoxicity developed in 8 patients each (13%), and a peripheral sensory neuropathy was observed in 17 cases (27%). Whether this type of dose-intensive therapy results in an improved therapeutic index in NSCLC is currently being evaluated in a randomized comparative trial versus standard-dose cisplatin therapy.

AB - To investigate chemotherapeutic dose intensity in advanced non-small-cell lung cancer (NSCLC), we evaluated a pharmacokinetically designed schedule of high-dose cisplatin (200 mg/m2 per 28-day cycle) plus mitomycin C. Between March 1987 and March 1989, 62 patients were registered for a phase II study of the Northern California Oncology Group (NCOG). The treatment schedule consisted of cisplatin in hypertonic saline given on a divided days 1 and 8 schedule (100 mg/m2 on each day) plus mitomycin C given at a dose of 8 mg/m2 on day 1 of each cycle. In 61 patients evaluable for response analysis, the overall response rate was 39% (24/61), with a complete response being achieved in 6% (4/61) of cases and a partial response, in 33% (20/61). The response according to reviewed histologic subtype included squamous, 53% of patients (10/19); large cell, 31% (4/13); and adenocarcinoma, 34% (10/29). The median survival for all patients was 19.3 weeks. The mean cisplatin and mitomycin C delivered dose intensities in this study were 45 mg/m2 per week (90% of the projected dose) and 1.5 mg/m2 per week (75%). The toxicity of this combination regimen in the 62 enrolled patients was significant but manageable. Leukopenia (WBC, <1,000/mm3) and thrombocytopenia (platelets, <25,000/mm3) occurred in 3# and 8% of patients treated, respectively. Dose-limiting renal toxicity and clinically significant ototoxicity developed in 8 patients each (13%), and a peripheral sensory neuropathy was observed in 17 cases (27%). Whether this type of dose-intensive therapy results in an improved therapeutic index in NSCLC is currently being evaluated in a randomized comparative trial versus standard-dose cisplatin therapy.

UR - http://www.scopus.com/inward/record.url?scp=0025614552&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025614552&partnerID=8YFLogxK

U2 - 10.1007/BF00685721

DO - 10.1007/BF00685721

M3 - Article

VL - 27

SP - 243

EP - 247

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 3

ER -